Neogenomics Inc.
NASDAQ:NEO 4:00:00 PM EDT
| Market Cap (Intraday) | 1.75B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 98.21 |
| 10-Day MA | $14.40 |
| 50-Day MA | $15.13 |
| 200-Day MA | $15.51 |
Neogenomics Inc. Stock, NASDAQ:NEO
9490 NeoGenomics Way, Suite 9, Fort Myers, Florida 33912
United States of America
Phone: +1.239.768.0600
Number of Employees: 2100
Description
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.